# Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

> **NCT07403435** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 22 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Serplulimab

## Key facts

- **NCT ID:** NCT07403435
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-15
- **Primary completion:** 2027-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07403435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07403435, "Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07403435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*